ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Daiichi Sankyo will close an active pharmaceutical ingredients (API) plant in Hiratsuka, Japan, by September 2017. Opened in 1962, the facility employs 150 people and is one of Daiichi Sankyo’s four API plants in Japan. The announcement came on the day the firm unveiled a five-year plan that calls for business streamlining and cost reductions. As part of its new strategy, oncology will become Daiichi Sankyo’s core business. The company noted that one of its most profitable drugs, the hypertension drug Olmesartan, will lose patent protection next year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter